Monopar Therapeutics (MNPR) Equity Ratio: 2016-2020
Historic Equity Ratio for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to 0.96.
- Monopar Therapeutics' Equity Ratio rose 6.42% to 0.96 in Q3 2020 from the same period last year, while for Sep 2020 it was 0.96, marking a year-over-year increase of 6.42%. This contributed to the annual value of 0.95 for FY2019, which is 0.04% up from last year.
- Latest data reveals that Monopar Therapeutics reported Equity Ratio of 0.96 as of Q3 2020, which was up 1.48% from 0.95 recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Equity Ratio peaked at 0.98 during Q4 2016, and registered a low of 0.91 during Q3 2019.
- Its 3-year average for Equity Ratio is 0.94, with a median of 0.95 in 2020.
- As far as peak fluctuations go, Monopar Therapeutics' Equity Ratio dropped by 6.15% in 2019, and later increased by 6.42% in 2020.
- Over the past 5 years, Monopar Therapeutics' Equity Ratio (Quarterly) stood at 0.98 in 2016, then fell by 0.93% to 0.97 in 2017, then fell by 2.39% to 0.95 in 2018, then rose by 0.04% to 0.95 in 2019, then increased by 6.42% to 0.96 in 2020.
- Its last three reported values are 0.96 in Q3 2020, 0.95 for Q2 2020, and 0.97 during Q1 2020.